While promising, cancer immunotherapy faces several challenges:
1. Immune-Related Adverse Events (irAEs): Overactivation of the immune system can lead to autoimmune reactions affecting various organs. 2. Resistance: Some tumors develop resistance to immunotherapy through various mechanisms, including upregulation of alternative immune checkpoints or loss of antigen presentation. 3. Patient Heterogeneity: Not all patients respond similarly to immunotherapy due to differences in genetic makeup, tumor microenvironment, and previous treatments.
